Mice without uPA, tPA, or plasminogen genes are resistant to experimental choroidal neovascularization

Investigative Ophthalmology and Visual Science

Volumn 44, Issue 4, 2003, Pages 1732-1739

  Rakic, Jean Marie ^a   Lambert, Vincent ^b   Munaut, Carine ^b   Bajou, Khalid ^b   Peyrollier, Karine ^b   Alvarez Gonzalez, Marie Luz ^b   Carmeliet, Peter ^c   Foidart, Jean Michel ^b   Noël, Agnès ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIN; FIBRINOGEN; MATRIX METALLOPROTEINASE; PLASMINOGEN; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; UROKINASE RECEPTOR;

AGED; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REGULATION; FEMALE; GENE FUNCTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; LASER; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA MACULA AGE RELATED DEGENERATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBRETINAL NEOVASCULARIZATION; WILD TYPE; ZYMOGRAPHY;

AGED; AGED, 80 AND OVER; ANIMALS; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE EXPRESSION; HUMANS; LASER COAGULATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PLASMINOGEN; RECEPTORS, CELL SURFACE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE PLASMINOGEN ACTIVATOR; URINARY PLASMINOGEN ACTIVATOR;

EID: 0037378714     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.02-0809     Document Type: Article

References (35)

1. Campochiaro PA. Retinal and choroidal neovascularization. J Cell Physiol. 2000;184:301-310.
2. Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol. 2001;21:1104-1117.
3. Blasi F. Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system. Thromb Haemost. 1999;82:298-304.
4. Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest. 1999; 103:1237-1241.
5. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000;2:737-744.
6. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;3:161-174.
7. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinasetype plasminogen activator system in cancer metastasis: a review. Int J Cancer. 1997;72:1-22.
8. Cavallaro U, Tenan M, Castelli V, et al. Response of bovine endothelial cells to FGF-2 and VEGF is dependent on their site of origin: relevance to the regulation of angiogenesis. J Cell Biochem. 2001; 82:619-633.
9. Carmeliet P, Collen D. Genetic analysis of blood vessel formation: role of endothelial versus smooth muscle cells. Trend Cardiovasc Med. 1997;7:271-281.
10. Devy L, Blacher S, Grignet-Debrus C, et al. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J 2002;16:147-154.
11. Bajou K, Noel A, Gerard RD, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med. 1998;4:923-928.
12. Bajou K, Masson V, Gerard RD, et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin: implications for antiangiogenic strategies. J Cell Biol. 2001;152:777-784.
13. Berman M, Winthrop S, Ausprunk D, Rose J, Langer R, Gage J. Plasminogen activator (urokinase) causes vascularization of the cornea. Invest Ophthalmol Vis Sci. 1982;22:191-199.
14. Grant MB, Guay C. Plasminogen activator production by human retinal endothelial cells of nondiabetic and diabetic origin. Invest Ophthalmol Vis Sci. 1991;32:53-64.
15. Das A, McGuire PG, Eriqat C, et al. Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes. Invest Ophthalmol Vis Sci. 1999;40:809-813.
16. Hattenbach LO, Allers A, Gumbel HO, Scharrer I, Koch FH. Vitreous concentrations of TPA and plasminogen activator inhibitor are associated with VEGF in proliferative diabetic vitreoretinopathy. Retina. 1999;19:383-389.
17. Lambert V, Munaut C, Noel A, et al. Influence of plasminogen activator inhibitor type I on choroidal neovascularization. FASEB J. 2001;15:1021-1027.
18. Lopez PF, Grossniklaus HE, Lambert HM, et al. Pathologic features of surgically excised subretinal neovascular membranes in agerelated macular degeneration. Am J Ophthalmol. 1991;112:647-656.
19. Lopez PF, Lambert HM, Grossniklaus HE, Sternberg P Jr. Welldefined subfoveal choroidal neovascular membranes in age-related macular degeneration. Ophthalmology. 1993;100:415-422.
20. Lambert V, Munaut C, Noel A, Werb Z, Foidart J-M, Rakic J-M. MMP-9 contributes to choroidal neovascularization. Am J Pathol. 2002;161:1247-1253.
21. Carmeliet P, Schoonjans L, Kieckens L, et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature. 1994;368:419-424.
22. Carmeliet P, Collen D. Development and disease in proteinasedeficient mice: role of the plasminogen, matrix metalloproteinase and coagulation system. Thromb Res. 1998;91:255-285.
23. Ploplis VA, French EL, Carmeliet P, Collen D, Plow EF. Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice. Blood. 1998;91:2005-2009.
24. Munaut C, Noel A, Weidle UH, Krell HW, Foidart JM. Modulation of the expression of interstitial and type-IV collagenases in coculture of HT1080 fibrosarcoma cells and fibroblasts. Invasive Metastasis. 1995;15:169-178.
25. Bugge TH, Kombrinck KW, Flick MJ, Daugherty CC, Danton MJ, Degen JL. Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. Cell. 1996;87:709-719.
26. Wang Y, Gillies C, Cone RE, O'Rourke J. Extravascular secretion of t-PA by the intact superfused choroid. Invest Ophthalmol Vis Sci. 1995;36:1625-1632.
27. Hackett SF, Campochiaro PA. Modulation of plasminogen activator inhibitor-1 and urokinase in retinal pigmented epithelial cells. Invest Ophthalmol Vis Sci. 1993;34:2055-2061.
28. Das A, McLamore A, Song W, McGuire PG. Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor. Arch Ophthalmol. 1999;117:498-503.
29. Carmeliet P, Moons L, Dewerchin M, et al. Receptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice. J Cell Biol. 1998;140:233-245.
30. Grossniklaus HE, Cingle KA, Yoon YD, Ketkar N, L'Hernault N, Brown S. Correlation of histologic 2-dimensional reconstruction and confocal scanning laser microscopic imaging of choroidal neovascularization in eyes with age-related maculopathy. Arch Ophthalmol. 2000;118:625-629.
31. Spraul CW, Lang GE, Grossniklaus HE, Lang GK. Histologic and morphometric analysis of the choroid, Bruch's membrane, and retinal pigment epithelium in postmortem eyes with age-related macular degeneration and histologic examination of surgically excised choroidal neovascular membranes. Surv Ophthalmol. 1999;44:10-32.
32. Hiraoka N, Allen E, Apel IJ, Gyetko MR, Weiss SJ. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell. 1998;95:365-377.
33. Diaz VM, Planaguma J, Thomson TM, Reventos J, Paciucci R. Tissue plasminogen activator is required for the growth, invasion, and angiogenesis of pancreatic tumor cells. Gastroenterology. 2002;122:806-819.
34. Heymans S, Luttun A, Nuyens D, et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med. 1999;5:1135-1142.
35. Rifkin DB, Mazzieri R, Munger JS, Noguera I, Sung J. Proteolytic control of growth factor availability. APMIS. 1999;107:80-85.